
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc. presents an attractive investment opportunity, as indicated by the raising of its 12-month price target based on a net present value (NPV) analysis, which highlights significant upside potential. The company's lead product, stenoparib, demonstrates promising and durable clinical benefits for patients with advanced recurrent ovarian cancer, especially those with limited treatment options available. Additionally, the strategic use of the proprietary Drug Response Predictor technology aims to enhance patient selection and clinical outcomes, further bolstering the company’s growth trajectory in the precision medicine sector.
Bears say
Allarity Therapeutics reported a net loss of $2.37 million, resulting in earnings per share (EPS) of $(0.15), which was better than estimated EPS of $(0.21), indicating ongoing financial challenges. The outlook remains negative due to significant balance sheet and liquidity risks, compounded by the potential failure of the company's product candidates to prove safety and efficacy in clinical trials, as well as regulatory hurdles. Additional concerns include difficulties in commercialization, obtaining reimbursement, competitive pressures, and broader macroeconomic factors impacting the biotech sector.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares